Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: The EPICOR study

Licia Iacoviello, Claudia Agnoli, Amalia De Curtis, Augusto Di Castelnuovo, Maria Concetta Giurdanella, Vittorio Krogh, Amalia Mattiello, Giuseppe Matullo, Carlotta Sacerdote, Rosario Tumino, Paolo Vineis, Giovanni De Gaetano, Salvatore Panico, Maria Benedetta Donati

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: We examined the association of plasminogen activator inhibitor-1 (PAI-1) levels with colorectal cancer, breast cancer, acute coronary syndrome (ACS) and ischaemic stroke. Design: Nested case-cohort study. Setting: The European Prospective Investigation into Cancer and Nutrition-Italy cohort. Participants: A centre-stratified random sample of 850 participants (286 men, 564 women) was selected as subcohort and compared with 303 colorectal cancers, 617 breast cancers, 688 ACS and 158 ischaemic strokes, in a mean follow-up of 9.11 years. Main outcomes and measures: Primary incident cases of colon cancer, breast cancer, ACS and ischaemic stroke. PAI-1 levels were measured in citrated plasma by ELISA. HR and 95% CI, adjusted by relevant confounders and stratified by centre, were estimated by a Cox regression model using Prentice method. Results: Individuals in the highest compared with the lowest quartile of PAI-1 had significantly increased risk of colorectal cancer (RR=2.28;95% CI 1.46 to 3.55; P for trend

Original languageEnglish
Article number12
JournalBMJ Open
Volume3
Issue number11
DOIs
Publication statusPublished - 2013

Fingerprint

Plasminogen Activator Inhibitor 1
Vascular Diseases
Breast Neoplasms
Acute Coronary Syndrome
Colorectal Neoplasms
Neoplasms
Stroke
Proportional Hazards Models
Colonic Neoplasms
Italy
Cohort Studies
Enzyme-Linked Immunosorbent Assay
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease : The EPICOR study. / Iacoviello, Licia; Agnoli, Claudia; De Curtis, Amalia; Di Castelnuovo, Augusto; Giurdanella, Maria Concetta; Krogh, Vittorio; Mattiello, Amalia; Matullo, Giuseppe; Sacerdote, Carlotta; Tumino, Rosario; Vineis, Paolo; De Gaetano, Giovanni; Panico, Salvatore; Donati, Maria Benedetta.

In: BMJ Open, Vol. 3, No. 11, 12, 2013.

Research output: Contribution to journalArticle

Iacoviello, Licia ; Agnoli, Claudia ; De Curtis, Amalia ; Di Castelnuovo, Augusto ; Giurdanella, Maria Concetta ; Krogh, Vittorio ; Mattiello, Amalia ; Matullo, Giuseppe ; Sacerdote, Carlotta ; Tumino, Rosario ; Vineis, Paolo ; De Gaetano, Giovanni ; Panico, Salvatore ; Donati, Maria Benedetta. / Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease : The EPICOR study. In: BMJ Open. 2013 ; Vol. 3, No. 11.
@article{a3c53130be0d40dc830625c79ae6aad8,
title = "Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: The EPICOR study",
abstract = "Objectives: We examined the association of plasminogen activator inhibitor-1 (PAI-1) levels with colorectal cancer, breast cancer, acute coronary syndrome (ACS) and ischaemic stroke. Design: Nested case-cohort study. Setting: The European Prospective Investigation into Cancer and Nutrition-Italy cohort. Participants: A centre-stratified random sample of 850 participants (286 men, 564 women) was selected as subcohort and compared with 303 colorectal cancers, 617 breast cancers, 688 ACS and 158 ischaemic strokes, in a mean follow-up of 9.11 years. Main outcomes and measures: Primary incident cases of colon cancer, breast cancer, ACS and ischaemic stroke. PAI-1 levels were measured in citrated plasma by ELISA. HR and 95{\%} CI, adjusted by relevant confounders and stratified by centre, were estimated by a Cox regression model using Prentice method. Results: Individuals in the highest compared with the lowest quartile of PAI-1 had significantly increased risk of colorectal cancer (RR=2.28;95{\%} CI 1.46 to 3.55; P for trend",
author = "Licia Iacoviello and Claudia Agnoli and {De Curtis}, Amalia and {Di Castelnuovo}, Augusto and Giurdanella, {Maria Concetta} and Vittorio Krogh and Amalia Mattiello and Giuseppe Matullo and Carlotta Sacerdote and Rosario Tumino and Paolo Vineis and {De Gaetano}, Giovanni and Salvatore Panico and Donati, {Maria Benedetta}",
year = "2013",
doi = "10.1136/bmjopen-2013-003725",
language = "English",
volume = "3",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease

T2 - The EPICOR study

AU - Iacoviello, Licia

AU - Agnoli, Claudia

AU - De Curtis, Amalia

AU - Di Castelnuovo, Augusto

AU - Giurdanella, Maria Concetta

AU - Krogh, Vittorio

AU - Mattiello, Amalia

AU - Matullo, Giuseppe

AU - Sacerdote, Carlotta

AU - Tumino, Rosario

AU - Vineis, Paolo

AU - De Gaetano, Giovanni

AU - Panico, Salvatore

AU - Donati, Maria Benedetta

PY - 2013

Y1 - 2013

N2 - Objectives: We examined the association of plasminogen activator inhibitor-1 (PAI-1) levels with colorectal cancer, breast cancer, acute coronary syndrome (ACS) and ischaemic stroke. Design: Nested case-cohort study. Setting: The European Prospective Investigation into Cancer and Nutrition-Italy cohort. Participants: A centre-stratified random sample of 850 participants (286 men, 564 women) was selected as subcohort and compared with 303 colorectal cancers, 617 breast cancers, 688 ACS and 158 ischaemic strokes, in a mean follow-up of 9.11 years. Main outcomes and measures: Primary incident cases of colon cancer, breast cancer, ACS and ischaemic stroke. PAI-1 levels were measured in citrated plasma by ELISA. HR and 95% CI, adjusted by relevant confounders and stratified by centre, were estimated by a Cox regression model using Prentice method. Results: Individuals in the highest compared with the lowest quartile of PAI-1 had significantly increased risk of colorectal cancer (RR=2.28;95% CI 1.46 to 3.55; P for trend

AB - Objectives: We examined the association of plasminogen activator inhibitor-1 (PAI-1) levels with colorectal cancer, breast cancer, acute coronary syndrome (ACS) and ischaemic stroke. Design: Nested case-cohort study. Setting: The European Prospective Investigation into Cancer and Nutrition-Italy cohort. Participants: A centre-stratified random sample of 850 participants (286 men, 564 women) was selected as subcohort and compared with 303 colorectal cancers, 617 breast cancers, 688 ACS and 158 ischaemic strokes, in a mean follow-up of 9.11 years. Main outcomes and measures: Primary incident cases of colon cancer, breast cancer, ACS and ischaemic stroke. PAI-1 levels were measured in citrated plasma by ELISA. HR and 95% CI, adjusted by relevant confounders and stratified by centre, were estimated by a Cox regression model using Prentice method. Results: Individuals in the highest compared with the lowest quartile of PAI-1 had significantly increased risk of colorectal cancer (RR=2.28;95% CI 1.46 to 3.55; P for trend

UR - http://www.scopus.com/inward/record.url?scp=84888121848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888121848&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2013-003725

DO - 10.1136/bmjopen-2013-003725

M3 - Article

C2 - 24231461

AN - SCOPUS:84888121848

VL - 3

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 11

M1 - 12

ER -